Stay updated with breaking news from Arthur Oubrie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Therapeutics developer Lead Pharmaceutical (Oss, Netherlands) and French medicinal chemistry and custom synthesis company Oxeltis, have been awarded an €800K ($842K) grant from EUREKA Eurostars for a three year project aimed at developing a first-in-class small molecule therapy for diffuse large B-cell lymphoma (DLBCL). Click to read more...
Dutch firm Lead Pharma and French company Oxeltis have been awarded an €800K grant from the 37-nation EUREKA intergovernmental network’s Euro...
Grant will fund three-year EPIGENEXT joint project aimed at developing first-in-class therapy for diffuse large B-cell lymphoma Oss, the Netherlands and Montpellier, France, June 8, 2022 – Lead Pharma, a privately held pharmaceutical company designing and developing innovative therapies for the treatment of immune-...